PharmaNews.eu
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
More Articles...
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
| Page 1 of 254 | ||||||||||||||||||||||||||||||||||||||||||||||
Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.
Merck (known as MSD outside the United States and Canada) today announced that the European Union has granted marketing approval for a new, single dose regimen of 'Ivemend'® (fosaprepitant) 150 mg. Fosaprepitant is used in adults in combination with other antiemetic medicines for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin (HEC)-based chemotherapy and moderately emetogenic chemotherapy (MEC).
Amgen (NASDAQ:AMGN), the world's largest biotechnology company, and Mustafa Nevzat Pharmaceuticals (MN) today announced an agreement under which Amgen will acquire 95.6 percent of shares in MN, a privately held Turkish pharmaceutical company, for an amount that values MN at US $700 million. The all-cash transaction will significantly expand Amgen's presence in Turkey and the surrounding region, which are large, fast-growing, priority markets for Amgen.
Nycomed, a Takeda Company, announced that Jostein Davidsen has been appointed Head of Emerging Markets in addition to his current role as Area Head of Russia/CIS. He will report to Frank Morich, EVP, International Operations (Americas/Europe), Takeda Pharmaceuticals International, and CEO of Nycomed. The appointment is effective immediately. Nycomed's presence in Emerging Markets was a key driver for Takeda to acquire Nycomed at the end of September 2011. These fast-growing markets are an important lever to achieve Takeda's sustainable growth aspirations as outlined in the 2011-2013 Mid-Range-Plan.
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced they have received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of Jentadueto® (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta® tablets, marketed under the trade name Trajenta® in Europe) and metformin in a single tablet taken twice daily.
Industry News
Abbott | Amgen | AstraZeneca | Bayer | Boehringer Ingelheim | Bristol-Myers Squibb | Genzyme | GlaxoSmithKline | Lilly | Merck | Merck KGaA | Novartis | Novo Nordisk | Nycomed | Pfizer | Roche | Sanofi | Schering-Plough | Shire | ...Submit News
More information
- Advertise / Contact Us
- Terms and Conditions
- Follow/Join us on:
